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background: The development and progression of heart failure (HF) is believed to be an inflammatory process. C-reactive protein (CRP) 
concentrations are elevated in patients with HF and associated with worse outcomes. Given the potential utility of CRP to guide therapy, this meta-
analysis sought to determine the treatment effect of CRP in patients with heart failure with reduced ejection fraction (HFrEF).
Methods: We searched MEDLINE, SCOPUS, and Cochrane Central from their inception through March 2013 for randomized-controlled trials in 
patients with an ejection fraction < 40% which measured baseline CRP or high-sensitive CRP (hsCRP) concentrations, reported readmission or 
mortality rates, and were published in English. Pooled odds ratios (ORs) and corresponding 95 percent confidence intervals (CI) were calculated 
using either a fixed-effect or random-effects model. Statistical heterogeneity and publication bias were addressed using the I2 statistic and Egger’s 
weighted regression statistics, respectively. Random-effects meta-regression was performed to evaluate the association between the treatment effect 
and baseline CRP or hsCRP in the treatment group.
results: Of the original 268 citations identified, seven studies, enrolling 14,897 subjects, were included in the analysis. Pooled analyses showed 
the interventions to have no significant effect on mortality (OR 0.98, 95% CI 0.90-1.06) or the composite of mortality and readmission (OR 0.95, 
95% CI 0.74-1.22) although a significant reduction in readmissions was seen (OR 0.89,95% CI 0.81-0.97). Meta-regression showed no significant 
association between baseline CRP concentrations and mortality (p=0.67), readmissions (0.71), or the composite of mortality and readmissions 
(p=0.63).
conclusion: Baseline CRP concentrations were not associated with therapeutic response in patients with HFrEF. Further study using serial CRP 
concentrations or combination with multiple biomarkers may be warranted.
